CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.
Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中国复发/难治性多发性骨髓瘤的真实世界管理存在高度异质性。这些发现强调了持续研究和循证指南的必要性，以优化患者预后。多发性骨髓瘤是一种难以治疗的血液癌症，随着疾病变化或初始治疗后复发，医生常需采用多种治疗方案。在中国，初始治疗后最常用的治疗方案尚不明确，患者接受每种治疗的时间也不清楚。为更好地了解这些治疗模式，我们调查了中国城市地区 120 名定期诊治多发性骨髓瘤患者的医生。结果显示，在疾病后期阶段，医生并无统一治疗策略。多种药物组合被处方使用，且没有一种治疗用于超过 10% 的患者。
多发性骨髓瘤（MM）是一种复杂的血液系统恶性肿瘤，其治疗格局正在迅速演变。中国一线以上治疗方案使用的真实世界数据有限。
我们分析了基于2024年对120名中国医生关于复发/难治性多发性骨髓瘤管理和治疗时长的调查数据，这些数据来自CancerMPact治疗架构数据库。描述性统计总结了二线及以后治疗中的方案选择与持续时间。
观察到治疗方案选择存在显著异质性，在所有治疗线中，没有任何单一方案在超过10%的患者中使用。在二线治疗中，66.3%的患者接受了基于硼替佐米、基于达雷妥尤单抗或达雷妥尤单抗联合硼替佐米的方案。常见的二线方案及使用时间包括卡非佐米、泊马度胺、地塞米松（9.6%；9.2个月），达雷妥尤单抗、硼替佐米、地塞米松（9.0%；8.1个月），以及达雷妥尤单抗、硼替佐米、来那度胺、地塞米松（7.6%；7.7个月）。在三线治疗中，主要方案为卡非佐米、泊马度胺、地塞米松（9.0%；7.3个月），达雷妥尤单抗、卡非佐米、地塞米松（8.2%；8.3个月），以及达雷妥尤单抗、硼替佐米、来那度胺、地塞米松（7.1%；8.1个月）。新型药物和嵌合抗原受体（CAR）-T细胞疗法在后续治疗线中的使用有所增加。
Multiple Myeloma (MM) is a complex hematologic malignancy with a rapidly evolving therapeutic landscape. Real-world data on treatment regimen use beyond the first line in China are limited.
We analyzed data from the CancerMPact Treatment Architecture database, based on a 2024 survey of 120 Chinese physicians regarding management and treatment durations for relapsed/refractory MM. Descriptive statistics summarized regimen selection and duration across second and later lines.
Substantial heterogeneity in regimen selection was observed, with no single regimen used in more than 10% of patients across all treatment lines. In second line, 66.3% of patients received a bortezomib-based, daratumumab-based, or daratumumab plus bortezomib-based regimen. Common second-line regimens and time of utilization included carfilzomib, pomalidomide, dexamethasone (9.6%; 9.2 months), daratumumab, bortezomib, dexamethasone (9.0%; 8.1 months), and daratumumab, bortezomib, lenalidomide, dexamethasone (7.6%; 7.7 months). In third line, top regimens were carfilzomib, pomalidomide, dexamethasone (9.0%; 7.3 months), daratumumab, carfilzomib, dexamethasone (8.2%; 8.3 months), and daratumumab, bortezomib, lenalidomide, dexamethasone (7.1%; 8.1 months). Novel agents and chimeric antigen receptor (CAR)-T cell therapies saw increased use in later lines.
Real-world management of relapsed/refractory MM in China is highly variable. These findings highlight the necessity for ongoing research and evidence-based guidelines to optimize patient outcomes. Multiple myeloma is a type of blood cancer that can be difficult to treat, and doctors often need to use several treatment approaches as the disease changes or returns after initial therapy. In China, it is not clear which treatments are most commonly used after the first round of initial therapy, or how long patients stay on each treatment. To better understand these treatment patterns, we surveyed 120 doctors across urban China who regularly care for people with multiple myeloma. Our findings showed that there is no single approach doctors use in these later stages. Many different medicine combinations are prescribed, and no treatment is used in more than 10% of patients. This wide range of treatment choices highlights the complexity of managing multiple myeloma in China today. Our research shows a need for clearer guidelines and more research to help inform clinical decision making.
MEMBER ACCOUNT
登录成功会直接打开下一页。
